.png)
Dr. Alessandro Giardini
.png){kind=small}
.png){kind=small}
.png){kind=small}
Few words unsettle a parent quite like "your child may need cholesterol medication." The mental image most people carry of statin treatment belongs to middle-aged adults, not to a child who plays football on Saturdays and argues about screen time. Hearing that suggestion can feel deeply counterintuitive.
This is a question Dr. Alessandro Giardini is asked often when discussing cholesterol level results with families. The concern is entirely reasonable. What the evidence actually shows, after more than two decades of research, is considerably more reassuring than most parents expect.
Statins have been studied in children with inherited cholesterol conditions since the late 1990s. The evidence now includes randomised trials, long-term follow-up studies, and registry data spanning twenty years. That is an unusually large evidence base for any paediatric medication.
The findings are consistent. Children treated with statins show significant reductions in LDL cholesterol without meaningful increases in serious adverse events. The landmark study that shifted clinical practice followed children with familial hypercholesterolaemia for twenty years and demonstrated measurably healthier arteries in adults who started treatment in childhood compared with those who began later.
Statins can occasionally cause muscle aches, mild liver enzyme changes, or stomach discomfort. These effects are uncommon in children, tend to be mild, and resolve when the dose is adjusted. Serious side effects are rare. Dr. Giardini monitors every child on statin therapy with regular blood tests and clinical reviews so that any issue is caught early.
This is the question parents most often hold back until the end of the appointment. Will a statin affect my child's growth? Could it interfere with puberty?
The data is reassuring. Studies tracking height, weight, pubertal development, and hormonal profiles in children on statins have not shown adverse effects on growth or maturation. Children on treatment follow the same growth trajectories as their unaffected siblings.
Statins reduce cholesterol production in the liver. They do not affect the hormonal pathways driving growth and puberty.
No child is started on a statin lightly. The process involves confirming that cholesterol is persistently and significantly elevated, establishing whether an inherited condition is responsible, and trialling dietary and lifestyle measures first. Medication is discussed only when the clinical picture warrants it.
The conversation is always collaborative. Dr. Giardini walks families through the reasoning, the evidence, and the monitoring plan. Parents who are not yet comfortable are given time to reflect and come back when they feel ready.
For a full overview of inherited cholesterol conditions, including diagnosis and treatment pathways, see the main page on high cholesterol in children.
Guidelines generally support starting from around age eight to ten in children with confirmed inherited cholesterol disorders, though exact timing depends on the individual child's cholesterol levels and family history. The decision is always case by case.
In children with inherited conditions such as familial hypercholesterolaemia, long-term treatment is usually recommended because the underlying genetic cause does not change. The plan is reviewed regularly as the child grows, and many young people manage their condition very comfortably as part of everyday life.
When mildly elevated cholesterol has no inherited cause, diet and activity are often sufficient. When a genetic condition produces significantly elevated LDL, lifestyle measures alone are unlikely to bring cholesterol into a safe range. Statins and healthy habits work together.
Twenty years of follow-up data is substantial by paediatric standards and has not revealed unexpected long-term harms. The cardiovascular risk of leaving significantly elevated LDL untreated is, by comparison, well documented and considerable.
Author: Dr. Alessandro Giardini, MD, PhD
Written 10/05/2026